BioMarin seeks UK approval to begin trial of Batten disease drug

04/3/2013 | Pharmaceutical Business Review Online

BioMarin Pharmaceutical filed an application with the U.K. Medicines and Healthcare Products Regulatory Agency seeking approval to initiate a Phase I/II trial of BMN-190, an experimental drug for neuronal ceroid lipofuscinosis type 2, a form of Batten disease. The firm expects patient enrollment for the trial to begin this year.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA